1.
Manufacturing costs of HPV vaccines for developing countries
by Clendinen, Chaevia
Vaccine, 2016, Vol.34 (48), p.5984-5989
2.
Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh
by Mahumud, Rashidul Alam
Vaccine, 2020-01-10, Vol.38 (2), p.165-172
3.
The cost-effectiveness of male HPV vaccination in the United States
by Chesson, Harrell W
Vaccine, 2011, Vol.29 (46), p.8443-8450
4.
Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine
by Gu, Ying
Vaccine, 2017-08-16, Vol.35 (35), p.4637-4645
5.
Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity
by Pan, Huirong
Vaccine, 2017-05-31, Vol.35 (24), p.3222-3231
6.
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis
by Kim, Jane J, Dr
The Lancet infectious diseases, 2010, Vol.10 (12), p.845-852
7.
Impact of vaccinating boys and men against HPV in the United States
by Elbasha, Elamin H
Vaccine, 2010, Vol.28 (42), p.6858-6867
8.
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
by Goldie, Sue J
Vaccine, 2008, Vol.26 (32), p.4080-4093
9.
10.
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States
by Chesson, Harrell W
Vaccine, 2012, Vol.30 (42), p.6016-6019
11.
Human papillomavirus vaccine approval in China: a major step forward but challenges ahead
by Pan, Xiong-Fei
The Lancet infectious diseases, 2016, Vol.16 (12), p.1322-1323
12.
A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda
by Ngabo, Fidèle
Vaccine, 2015, Vol.33 (51), p.7357-7363
13.
Factors associated with human papillomavirus vaccination among young adult women in the United States
by Williams, Walter W
Vaccine, 2013, Vol.31 (28), p.2937-2946
14.
Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects
by Wigle, Jannah
Vaccine, 2013, Vol.31 (37), p.3811-3817
15.
Race, Ethnicity, and Income Factors Impacting Human Papillomavirus Vaccination rates
by Jeudin, Patricia, MD
Clinical therapeutics, 2014, Vol.36 (1), p.24-37
16.
Modeling Cervical Cancer Prevention in Developed Countries
by Kim, Jane J
Vaccine, 2008, Vol.26 (Suppl 10), p.K76-K86
17.
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis
by Van de Velde, Nicolas
Vaccine, 2010, Vol.28 (33), p.5473-5484
18.
Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review
by Fesenfeld, Michaela
Vaccine, 2013, Vol.31 (37), p.3786-3804
19.
Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras
by Aguilar, Ida Berenice Molina
Vaccine, 2014, Vol.33, p.A167-A173
20.
Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination
by Ng, Siok Shen
Vaccine, 2018-05-03, Vol.36 (19), p.2529-2544
